Akcije

Scripta Medica
kako citirati ovaj članak
podeli ovaj članak

Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:3

Sadržaj

članak: 1 od 1  
Back povratak na rezultate
2020, vol. 51, br. 4, str. 215-216
Scripta Medica, volume 51, 2020: A short overview
(naslov ne postoji na srpskom)
Scripta Medica

e-adresamilos.stojiljkovic@med.unibl.org
Ključne reči: Scripta Medica; Biomedical journal; Editorial process; Research articles
Sažetak
(ne postoji na srpskom)
This editorial presents the analysis of volumes 50 (2019) and 51 (2020) of Scripta Medica. Original articles made 53 % of 80 articles published in these two volumes. Article rejection rate was 38 %. Mean duration of period until reaching the first decision on an article was 20 days, while mean time until reaching the final decision was 31 days. Mean time needed for accepting the revised manuscript was 3 days, reflecting a significant decrease from 5 days in 2019 to 2 days in 2020. Mean time needed for reaching a decision to reject an article was 7 days. Coverage of the journal included both basic and clinical research and a considerable space was devoted to articles on COVID-19. Further efforts will be made in order to reach a more international recognition of the journal.

Introduction

On 6 August 2018 a new Editorial Office and Editorial and Advisory Boards of the scientific biomedical journal Scripta Medica were formed [1]. Since 2019, the journal started to appear quarterly (in March, June, September and December). During these two years, a new layout of the journal was introduced and Scripta Medica gained the Directory of Open Access Journals (DOAJ) coverage. End of this tumultuous year is a good occasion to look back at the accomplishments of Scripta Medica, in order to ascertain its strong points but also the areas where some improvement would be necessary.

Volume 51 (2020) contained 48 articles, 50% more than the volume 50 Table 1.

Table 1. Structure of volumes 50 (2019) and 51 (2020) of Scripta Medica

2019 2020 Total
Type of article Number % Number % Number %
Editorial 4 12.5 4 8.33 8 10.00
Letters to the Editor 0 0.00 1 2.08 1 1.25
Original 15 46.88 27 56.25 42 52.5
Review 1 3.13 3 6.25 4 5.00
Current topic 2 6.25 2 4.17 4 5.00
Special 2 6.25 1 2.08 3 3.75
History of medicine 1 3.13 3 6.25 4 5.00
Professional 2 6.25 2 4.17 4 5.00
Case report 5 15.63 4 8.33 9 11.25
Obituary 0 0.00 1 2.08 1 1.25
Total 32 100 48 100 80 100

It can be noticed that this increase was accompanied by the increase in percentage of original articles and the decrease in the percentage of case reports.

A total of 140 manuscripts was received during the last two years and their status is given in Table 2.

Table 2. Structure of volumes 50 (2019) and 51 (2020) of Scripta Medica

2019 2020 Total
Decision status Number % of decided Number % of decided Number % of decided
Received 53 87 140
Decided 49 100.00 85 100.00 134 100
Rejected 17 34.69 34 40.00 51 38.06
Accepted 32 65.31 51 60.00 83 61.94
a) in current year 30 61.22 48 56.47 78 58.21
b) not in current year 2 4.08 3 3.53 5 3.73
Pending review 4 6 6

The rejection rate was 35% in 2019 and it was increased to 41% in 2020, resulting in the overall rejection rate of 38%.

Efficacy of critical phases of processing of the received manuscripts is presented in Table 3.

Table 3. Duration of decision-making process, Scripta Medica

2019 2020 Total
Editorial milestone Mean ± SD Range Mean ± SD Range Mean ± SD Range
First decision (days) 16.73 ± 13.42 1-58 22.21 ± 35.85 1-211 19.96 ± 28.43 1-211
Accepted (days) 31.00 ± 23.69 2-126 27.53 ± 39.37 1-214 30.76 ± 38.87 1-216
Revision-acception (days) 5.39 ± 4.88 1-18 1.60 ± 1.38 1-9 3.11 ± 3.72 1-18
Rejection (days) 5.50 ± 8.03 1-20 5.59 ± 8.27 1-31 6.87 ± 11.55 1-61

For those manuscripts that were eventually accepted, mean time period until the first editorial decision was made was 20 days, while the mean final acceptance time was 31 days. This relatively long time was a consequence of the lengthy reviewing process. It can be seen that the mean acceptance time after receiving peer-reviews was only 3 days, reflecting a sharp decrease from 5 days in 2019 to only 2 in 2020, while mean time for reaching a decision to reject the submission was 7 days.

Regarding the content of the volume 51, an effort was made to present results of both basic and clinical research. At the same time, a considerable space was dedicated to the coverage of COVID-19 pandemic [2][3][4][5][6][7][8][9][10]. It is an intention of the Editorial Board to continue to diversify the content of Scripta Medica and improve the editorial process in order to make it more attractive for international audience.

Dodatak

Acknowledgements

The author wishes his gratitude to Dr Žana M Maksimović for her help in providing the statistical analysis of the Scripta Medica editorial database.

Conflict of interest

None.

References

1.Stojiljković MP. On the occasion of the fiftieth volume of the Scripta Medica (Banja Luka). Scripta Medica. 2019;50(4):145-147. [Crossref]
2.Mijović B. COVID-19: Lessons learned. Scripta Medica. 2020;51(1):1-5. [Crossref]
3.Igić R. Pharmacologist's view of the new corona virus. Scripta Medica. 2020;51(1):6-8. [Crossref]
4.Stojiljković MP. COVID-19 pandemic, passing of professor Folke Sjöqvist and other topics. Scripta Medica. 2020;51(2):67-68. [Crossref]
5.Bhandari S, Sharma R, Shaktawat AS, Banerjee S, Patel B, Tak A, et al. COVID-19 related mortality profile at a tertiary care centre: A descriptive study. Scripta Medica. 2020;51(2):69-73. [Crossref]
6.Aćimović J, Jandrić L, Đakovic-Dević J, Bojanić J, Subotić B, Radojčić T, et al. Epidemiological characteristics of COVID-19 infection in the Republic of Srpska: A hundred days survey. Scripta Medica. 2020;51(2):74-80. [Crossref]
7.Janković S. Current status and future perspective of coronavirus disease 2019: A review. Scripta Medica. 2020;51(2):101-109. [Crossref]
8.Stajić M, Maksimović ŽM, Verhaz A. COVID-19 pneumonia: When negative RT-PCR testing does not rule out the disease. Scripta Medica. 2020;51(2):120-123. [Crossref]
9.Janković SM. Antiviral therapy of COVID-19. Scripta Medica. 2020;51(3):131-133.
10.Bhandari S, Shaktawat AS, Tak A, Patel B, Shukla J, Singhal S, et al. Relationship between blood group phenotypes (ABO, Rh and Kell) and nCOVID-19 susceptibility: A retrospective observational study. Scr Med. 2020;51(4):217-239. [Crossref]
Reference
Aćimović, J., Jandrić, L., Đakovic-Dević, J., Bojanić, J., Subotić, B., Radojčić, T., Rodić-Vukmir, N., Zeljković, B. (2020) Epidemiological characteristics of COVID-19 infection in the Republic of Srpska: A hundred days survey. Scripta Medica, vol. 51, br. 2, str. 74-80
Bhandari, S., Shaktawat, A.S., Tak, A., Patel, B., Shukla, J., Singhal, S., Gupta, K., Gupta, J., Kakkar, S., Dube, A., Dia, S., Dia, M., Wehner, T.C. (2020) Relationship between blood group phenotypes (ABO, Rh and Kell) and nCOVID-19 susceptibility: A retrospective observational study. Scr Med, 51(4): 217-239
Bhandari, S., Sharma, R., Shaktawat, A.S., Banerjee, S., Patel, B., Tak, A., Meena, D., Agarwal, A., Gupta, V., Sharma, S., Mahavar, S., Chejara, R.S., Rankawat, G., Gupta, K., Gupta, J. (2020) COVID-19 related mortality profile at a tertiary care centre: A descriptive study. Scripta Medica, vol. 51, br. 2, str. 69-73
Igić, R. (2020) Pharmacologist's view of the new corona virus. Scripta Medica, vol. 51, br. 1, str. 6-8
Janković, S. (2020) Current status and future perspective of coronavirus disease 2019: A review. Scripta Medica, vol. 51, br. 2, str. 101-109
Janković, S.M. (2020) Antiviral therapy of COVID-19. Scripta Medica, vol. 51, br. 3, str. 131-133
Mijović, B. (2020) COVID-19: Lessons learned. Scripta Medica, vol. 51, br. 1, str. 1-5
Stajić, M., Maksimović, Ž.M., Verhaz, A. (2020) COVID-19 pneumonia: When negative RT-PCR testing does not rule out the disease. Scripta Medica, vol. 51, br. 2, str. 120-123
Stojiljković, M.P. (2019) On the occasion of the fiftieth volume of the Scripta Medica (Banja Luka). Scripta Medica, vol. 50, br. 4, str. 145-147
Stojiljković, M.P. (2020) COVID-19 pandemic, passing of professor Folke Sjöqvist and other topics. Scripta Medica, vol. 51, br. 2, str. 67-68
 

O članku

jezik rada: engleski
vrsta rada: uvodnik
DOI: 10.5937/scriptamed51-30059
primljen: 28.12.2020.
prihvaćen: 28.12.2020.
objavljen u SCIndeksu: 12.01.2021.
Creative Commons License 4.0

Povezani članci

Nema povezanih članaka